April 26, 2023 10:48 AM EDTUpdated 05:28 PM

Novartis' PNH drug succeeds in PhIII and will go to FDA, setting up battle with AstraZeneca

Lei Lei Wu

News Reporter

Novartis on Wednesday shared more details from its successful late-stage trial of iptacopan, its drug for the rare blood disease PNH, that it hopes will …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis' PNH drug succeeds in PhIII and will go to FDA, setting up battle with AstraZeneca

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Lasker Award goes to three scientists who pioneered research behind GLP-1 drugs

Aligos’ trial for oral MASH treatment succeeds, but placebo group shows odd trend

FDA inspectors discover trucks carrying torn-up records leaving Indian generics factory

Exclusive: Flagship-backed Valo Health loses interim CEO ahead of key Phase 2 readout

Stem cell startup spun out of George Church’s lab raises $75M

Breaking down silos with a new quantitative approach to drug development

No­var­tis' PNH drug suc­ceeds in PhI­II and will go to FDA, set­ting up bat­tle with As­traZeneca

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Novartis' PNH drug succeeds in PhIII and will go to FDA, setting up battle with AstraZeneca